[Acute pancreatitis during the treatment of BH-AC AMP regimen for acute non-lymphocytic leukemia].
D015250:Aclarubicin; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003561:Cytarabine / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects; D008875:Middle Aged; D009279:Naphthacenes / Q000009:adverse effects; D010195:Pancreatitis / Q000139:chemically induced*; D011239:Prednisolone / Q000009:adverse effects
D009279:Naphthacenes; D003561:Cytarabine; D015250:Aclarubicin; D011239:Prednisolone; D015122:Mercaptopurine